🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We have 2 trials of bispecific antibodies in lung cancer open and running Chelsea and Westminster Hospital In fact, recruited the first patients in Europe to both of these 🦸

Thank you OncoDaily for highlighting my and these other posts from #ESMO24. There was so much news - great way to see all. ESMO - Eur. Oncology

🫁Radioligand Therapy Offers Hope to Lung Cancer Patients - Oncogene Cancer Research oncodaily.com/insight/148167 #Cancer #LCSM #CancerTreatment #Innovation #MedEd #MedNews #Health #Medicine #MedTwitter #OncoDaily #Oncology

Today is the #WorldCancerResearchDay a great opportunity to celebrate all the discoveries and big steps that allow advance in patient care. Proud of our team at The James Ohio State Medical Oncology and their amazing contributions in the field.

Our next ALKtALK is this Sunday (9/29) at 5pm ET. Dr. JessicaJLinMD will provide an update on the #research highlights from IASLC #WCLC24 & #ESMO24 conferences. As usual, she'll also take questions from our ALK+ cancer community. Don't miss this! See alkpositive.org/alktalk

Mel, a mum of 3 living in E London w her partner Sarah, had an x-ray to confirm Long Covid when a tumour was found. It turned out to be 'curable' EGFR lung cancer. 4 yrs later Mel's now stage 4. Read more & why she believes in the power of research oncogeneresearch.org/mels-story #LCSM

Our symposium for lung cancer patients & caregivers, discussing where research addresses unmet needs for immunotherapy, palliative care, telemedicine, KRAS, advocacy, small-cell and brain metastasis. Register & get ready with your questions for this amazing panel on Nov 4. #lcsm

Fantastic work from Davare Lab on oncogenic potential of #ROS1 extracellular domain (ECD) which doesn’t necessarily require fusion partner to sustain oncogenesis. The ROS1ders, Inc.

Nice to be recognised! Of course I am just one of a bigger team! Uganda Cancer Institute

Tonight's ALKtALK with Dr. JessicaJLinMD has just kicked off at the earlier time than usual. Do join us to hear all the latest research unveiled during #WCLC24 & #ESMO24, and a general talk on all things ALK lung cancer. Join us now: 👉alkpositive.org/alktalk

Following the latest CROWN data, those w ALK lung cancer want to understand what resistance to first line Lorlatinib looks like & any next 2L therapy. While the data is not quite there, Dr. JessicaJLinMD shared this initial info from #WCLC24. The ALKtALK replay out soon. #LCSM

Yvonne Diaz JessicaJLinMD IASLC ESMO - Eur. Oncology MassGeneral News Summer Farmen At last evening's ALKtALK, this chart generated a lot of questions. Important to understand why not all ALK patients move to a second line inhibitor after their first line treatment. Stay tuned for the replay of our ALKtALK - out this week. Thanks Dr. JessicaJLinMD! #LCSM

TODAY IS THE DEADLINE for submitting abstracts for the EGFR Resisters Research Summit! #EGFR EGFR Resisters #LCSM

Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas nature.com/articles/s4139…

Repurposing approved meds may speed up options for patients. Gilteritinib is FDA-approved for FLT3-mutated AML. U-M Rogel Cancer Center is studying use of gilteritinib in ALK. Article shows cholesterol inhibition enhances response of gilteritinib in lung cancer👇 nature.com/articles/s4141…

Wonderful to gather in Madrid for the semi-annual LuCE members meeting under the theme “Unlocking our collective power.” Great to see so many new members joining to use our collective voices to improve lung cancer outcomes. #StrongerTogether#LCSM

Systematic review & network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as 1L treatment for advanced ALK-NSCLC. lungcancerjournal.info/article/S0169-… ALK+ International ALK Positive LCAM Coalition

Great interactive day 2 at the Lung Cancer Europe Members meeting sharing best practice and there have been some great initiatives we have heard about. Great being one of the ‘oncogene girls’ representing the UK 😉EGFR Positive Lung Cancer UK Oncogene Cancer Research Lung Cancer Europe

Two brilliant days with this exceptional group of individuals. Thank you to our speakers, members, executive team & our moderator/facilitator - Kathy Redmond. Special thanks to my fellow board members. It's my privilege serving as your Lung Cancer Europe president ❤️

Great to see a blood test for the detection of lung cancer is one step closer w the work from University of York’s Cizzie Biotech & Moffitt Cancer Center. Based on the discovery of the CIZ1B biomarker. A step fwd in early detection. york.ac.uk/news-and-event…